ADDvise receives allocation decision worth approximately SEK 48 million

16-02-2023   Regulatory press release

ADDvise Group AB (publ)’s subsidiary Hettich Labinstrument AB has received an allocation decision from Region Västra Götaland worth approximately SEK 48 million. The allocation decision consists of delivery of equipment for blood- and urine specimen collection during a four-year period starting May 2023.

The allocation decision can be appealed up until February 25, 2023.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se


Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on February 16, 2023 at 16:50 CET.
 

About ADDvise Group
 

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

 

Latest press releases

Year-end report 2022, January 1-December 31

Regulatory

October–December 2022 Net revenue for the period was SEK 320.3 million (155.0), an increase of 106.6 %. Organic growth was 5.5 %. Orders received for the period was SEK 517.7 million (177.6), an increase of 191.5 %. Organic growth was 7.7 %. Adjusted EBITDA for the period was SEK 85.8 million (19.0) EBITDA for the…

ADDvise presents financial targets for 2023

Regulatory

The Board of Directors of ADDvise Group has adopted financial targets for the financial year 2023: -          Net sales pro forma rolling 12 months shall by the end of the year reach SEK 1.6 billion. -          EBITDA pro forma rolling 12 months shall by the end of the year reach SEK 330 million. The below…

ADDvise signs Letter of Intent to acquire Diabetic Supplies Inc.

Regulatory

ADDvise Group has signed a Letter of Intent with the shareholder of Diabetic Supplies Inc. (”Diabetic Supplies” or the “Company”) regarding an acquisition of all shares in Diabetic Supplies. Diabetic Supplies is based in Columbus, Ohio, USA and is a distributor of medical devices for diabetic patients. The Company distributes, among other things, continuous glucose…